Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PNLIP | P16233 | 9/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170612 | 0.89 | FFAR1 (0.51) | FFAR1PNLIPAPPACACBSTK39 | |
| SCHEMBL2171656 | 0.84 | EPHX1 (0.49) | FFAR1APPPTGS2 | |
| SCHEMBL23922346 | 0.81 | FFAR1 (0.56) | FFAR1MAPTNPSR1PNLIP | |
| SCHEMBL10964062 | 0.78 | FFAR1 (0.57) | FFAR1F7ACACB | |
| SCHEMBL607803 | 0.77 | EPHX1 (0.58) | APP | |
| SCHEMBL7794207 | 0.77 | EPHX1 (0.58) | APP | |
| SCHEMBL607802 | 0.77 | EPHX1 (0.58) | APP | |
| SCHEMBL21620367 | 0.76 | FFAR1 (0.65) | FFAR1MAPTF7 | |
| SCHEMBL5673527 | 0.75 | APP (0.53) | APP | |
| SCHEMBL30002874 | 0.75 | APP (0.53) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |